The U.S. SGLT2 Inhibitors Market is projected to grow from USD 5.49 Billion in 2025 to USD 11.06 Billion by 2035, while ...
Cardiovascular-Kidney-Metabolic (CKM) syndrome links heart disease, kidney disease, obesity, and diabetes. New guidelines ...
Heart failure affects more than 64 million people worldwide and remains a leading driver of cardiovascular morbidity and mortality. Adverse cardiac ...
Amram Kahn, MD, shares strategies for reconciling disparate clinical recommendations to optimize medication regimens for ...
MedPage Today on MSN
Chronic Kidney Disease Increasingly Driven By Diabetes
Despite treatment advances, kidney disease burden remained unchanged over the past decade ...
Chronic kidney disease (CKD) is common, largely silent and serious. Most people who have the condition do not realize they ...
Sodium-glucose cotransporter 2 inhibitors (SGLT2is) may be prescribed to people with heart failure, chronic kidney disease, ...
New guidelines may soon make the disorder known as CKM syndrome a common diagnosis.
Patients with chronic kidney disease and type 2 diabetes receiving pharmacist-led outreach were nearly twice as likely to start an SGLT2 inhibitor as those receiving usual care.
MedPage Today on MSN
A Better Idea of When Mild HCM Is Likely to Go Downhill Fast
Natural history study probes predictors of worsening in mild disease ...
Chronic kidney disease (CKD) is common, largely silent, and serious. Most people who have the condition do not realize they ...
GP practices will be monitored by ICBs on ‘immediate’ priorities to improve prevention and care for patients with cardiovascular disease, the Government has announced. The Department of Health and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results